GSK Corp - GSK Net earnings per share (EPS TTM)

Official company branding of GlaxoSmithKline plc (GSK)

GSK plc is aggressively updating its portfolio by investing in vaccine R&D and oncology. The rolling earnings per share history demonstrates financial resilience, with the current mark equal to 2.85. HIV medications provide a stable cash flow, creating a reliable revenue base. Meanwhile, the company is optimizing costs by outsourcing clinical trials and packaging to third-party contractors.

GSK (GSK plc) Net earnings per share for the last four quarters history from 07/04/2022 to 11/12/2026

Analytical breakdowns for GSK plc

- current quotes and average value forecast:
Price Chart GSK Corp|GSK - Price Target Chart
- issuer market value details:
Market Capitalization GlaxoSmithKline|GSK - Business Value
- business book valuation details:
Book Value per Share GSK|GSK - Book Valuation of Business|Market Value to Book Value Ratio gsk.com|GSK - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Capital GSK plc|GSK - Long-Term Indebtedness to Equity|Short-Term Debt to Capital GSK Corp|GSK - Company Total Indebtedness|Debt to Book Capitalization Ratio GlaxoSmithKline|GSK - Long-Term Debt Volume|Company Short-Term Debt GSK|Quick Liquidity Indicator gsk.com
- net income and valuation multiples indicators:
GSK - Final Profit|Expected Profit GSK plc|GSK - Market Cap to Net Income|Future Price to Earnings GSK Corp|GSK - Price/Earnings to Growth Ratio|EV/EBITDA Multiple GlaxoSmithKline|GSK - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) GSK|GSK - Net earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months gsk.com|GSK - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year GSK plc
Comprehensive company analysis:GSK - gsk.com
Manufactured products of GlaxoSmithKline plc

Stable demand for GSK plc (GSK) humanitarian pharmaceuticals amid minimal geopolitical risks ensures predictable cash flow generation. This metric is calculated as the ratio of total net income to the number of shares outstanding; therefore, the 12-month earnings per share history allows for an objective assessment of the real return on capital and the determination of the asset's fair value.

Competitors of GSK plc

LLY - Earnings per share for the last twelve months|ABBV: Earnings per share for the last twelve months|AZN: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NVS|MRK (Merck Sharp & Dohme) - Net earnings per share (EPS TTM)|Novo Nordisk Group (NVO) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Amgen Inc. (AMGN)|pfizer.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) SNY (Sanofi S.A.)|Net earnings per share for the trailing year Bristol Myers Squibb Company|Takeda Pharmaceutical Company Limited - Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Teva Pharmaceutical Industries (TEVA)|Dr. Reddy's Laboratories (RDY) - Earnings per share for the last twelve months|VTRS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Roivant Sciences|Net earnings per share (EPS TTM) Zai Lab Ltd|Net earnings per share for the last 12 months BHC (Valeant Pharmaceuticals)|COSM (Cosmos Health Inc) - Earnings per share for the trailing year